What is the latest BALPHARMA stock price?
The latest stored price for BALPHARMA is Rs 100.67 as of 2026-09-18.
gimli
BALPHARMA stock AI analysis
BALPHARMA Stock AI Analysis: Price, PE, 50DMA, Shareholding and Peers
BAL PHARMA LTD. is a small-cap stock in Healthcare. This Gimli page shows the latest available BALPHARMA price, returns, 50DMA/200DMA trend, PE, ROE, ROCE, financials, shareholding pattern, and industry peers for Indian stock screening research.
Price
₹100.67
1W return
-5.22%
1M return
+18.03%
3M return
+14.67%
6M return
+46.05%
1Y return
+19.56%
Market cap
₹160.28 cr
PE
25.52
PB
1.95
ROE
+7.87%
ROCE
+9.69%
RSI
58.40
Turnover
₹0.25 cr
Why it can matter in screens
- Momentum: BALPHARMA is above 50DMA, above 200DMA; RSI is 58.40.
- Returns: 1D -1.75%, 1W -5.22%, 1M +18.03%, 3M +14.67%, 1Y +19.56%.
- Trend levels: 52W high ₹124.60, 52W low ₹76.01, off high -19.21%.
- Liquidity: latest turnover is ₹0.25 cr; volume vs 20D is +0.19%.
- Valuation/profitability: PE 25.52, PB 1.95, ROE +7.87%, ROCE +9.69%.
- Growth: 3Y sales CAGR +1.09%, 3Y profit CAGR +34.68%.
Quick Answers
Is BALPHARMA above its 50DMA and 200DMA?
BALPHARMA is above 50DMA, above 200DMA. The latest 50DMA is 89.84 and the latest 200DMA is 79.34.
What are BALPHARMA PE, ROE and ROCE?
BALPHARMA has PE 25.52, ROE +7.87%, and ROCE +9.69% in Gimli's latest available snapshot.
How has BALPHARMA performed recently?
BALPHARMA has returned +18.03% over 1 month, +14.67% over 3 months, and +19.56% over 12 months in the latest stored data.
Is this stock page investment advice?
No. This page is a data snapshot for screening and research. It is not buy, sell, legal, tax, or investment advice.
Financials and Ownership
Quarterly income statement
| Period | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-03-31 | 84.08 cr | 10.33 cr | 3.59 cr | 2.26 |
| 2025-12-31 | 87.69 cr | 9.87 cr | 1.78 cr | 1.12 |
| 2025-09-30 | 74.02 cr | 6.85 cr | 0.71 cr | 0.45 |
| 2025-06-30 | 65.87 cr | 6.78 cr | 0.20 cr | 0.13 |
| 2025-03-31 | 81.88 cr | 8.72 cr | 5.43 cr | 3.40 |
| 2024-12-31 | 73.15 cr | 8.26 cr | 0.48 cr | 0.33 |
| 2024-09-30 | 73.69 cr | 7.49 cr | n/a | 0.65 |
| 2024-06-30 | 74.36 cr | 7.28 cr | 0.26 cr | 0.16 |
Annual income statement
| Year | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-03-31 | 311.66 cr | 33.83 cr | 6.28 cr | nan |
| 2025-03-31 | 303.08 cr | 31.76 cr | 7.22 cr | 4.56 |
| 2024-03-31 | 339.22 cr | 33.60 cr | 7.39 cr | 4.96 |
| 2023-03-31 | 301.71 cr | 24.37 cr | 2.57 cr | 1.67 |
| 2022-03-31 | 286.86 cr | 27.10 cr | 8.58 cr | 3.79 |
Balance sheet
| Period | Assets | Cash | Debt | Equity |
|---|---|---|---|---|
| 2026-03-31 | 375.54 cr | 2.30 cr | 159.52 cr | 82.25 cr |
| 2025-03-31 | 335.69 cr | 1.75 cr | 150.41 cr | 77.40 cr |
| 2024-03-31 | 319.84 cr | 4.20 cr | 142.25 cr | 71.97 cr |
| 2023-03-31 | 313.17 cr | 1.49 cr | 133.08 cr | 63.70 cr |
| 2022-03-31 | 260.53 cr | 1.11 cr | 106.66 cr | 58.49 cr |
Cash flow
| Period | OCF | FCF | Cash change |
|---|---|---|---|
| 2026-03-31 | 30.44 cr | 8.06 cr | n/a |
| 2025-03-31 | 20.32 cr | 1.53 cr | n/a |
| 2024-03-31 | 22.81 cr | 11.83 cr | n/a |
| 2023-03-31 | -1.54 cr | -16.18 cr | n/a |
| 2022-03-31 | 26.80 cr | 18.33 cr | n/a |
Shareholding Trend
| Period | Promoter | FII/FPI | DII | MF | Retail | Pledge |
|---|---|---|---|---|---|---|
| 2026-06-30 | +50.86% | +0.15% | +0.00% | +0.00% | +48.99% | +0.00% |
| 2026-03-31 | +50.86% | +0.14% | +0.00% | +0.00% | +49.01% | +0.00% |
| 2025-12-31 | +50.86% | +0.14% | +0.00% | +0.00% | +49.01% | +0.00% |
| 2025-09-30 | +50.86% | +0.22% | +0.00% | +0.00% | +48.92% | +0.00% |
| 2025-06-30 | +50.86% | +0.15% | +0.00% | +0.00% | +48.99% | +0.00% |
| 2025-03-31 | +50.86% | +0.14% | +0.00% | +0.00% | +49.00% | +0.00% |
| 2024-12-31 | +50.86% | +0.14% | +0.00% | +0.00% | +49.00% | +0.00% |
| 2024-09-30 | +50.86% | +0.13% | +0.00% | +0.00% | +49.01% | +0.00% |
| 2024-06-30 | +51.23% | +0.13% | +0.00% | +0.00% | +48.64% | +0.00% |
| 2024-03-31 | +51.23% | +0.13% | +0.00% | +0.00% | +48.64% | +0.00% |
| 2023-12-31 | +51.23% | +0.13% | +0.00% | +0.00% | +48.64% | +0.00% |
| 2023-09-30 | +51.61% | +0.14% | +0.00% | +0.00% | +48.25% | +0.00% |
| 2023-06-30 | +51.61% | +0.17% | +0.00% | +0.00% | +48.23% | n/a |
| 2023-03-31 | +51.61% | +0.17% | +0.00% | +0.00% | +48.23% | +0.00% |
| 2022-12-31 | +51.61% | +0.18% | +0.00% | +0.00% | +48.21% | +0.00% |
| 2022-09-30 | +52.00% | +0.20% | +0.00% | +0.00% | +47.80% | +0.00% |
| 2022-06-30 | +52.00% | +0.00% | +0.30% | n/a | n/a | +0.00% |
| 2022-04-13 | +52.00% | +0.00% | +0.30% | n/a | n/a | +0.00% |
| 2022-03-31 | +49.57% | +0.00% | +0.31% | n/a | n/a | +0.00% |
| 2021-12-31 | +49.57% | +0.00% | +0.31% | n/a | n/a | +0.00% |
Industry Peers
| Symbol | Name | Mcap | PE | ROE | 1Y |
|---|---|---|---|---|---|
| SUNPHARMA | SUN PHARMACEUTICAL IND L | 440,829.82 cr | 36.388220 | +15.50% | +11.45% |
| DIVISLAB | DIVI S LABORATORIES LTD | 248,876.81 cr | 85.407280 | +18.37% | +53.39% |
| TORNTPHARM | TORRENT PHARMACEUTICALS L | 163,807.57 cr | 75.106636 | +17.33% | +35.67% |
| APOLLOHOSP | APOLLO HOSPITALS ENTER. L | 128,608.22 cr | 65.670049 | +21.03% | +13.94% |
| ZYDUSLIFE | ZYDUS LIFESCIENCES LTD | 116,723.14 cr | 26.011308 | +16.04% | +10.70% |
| CIPLA | CIPLA LTD | 112,647.78 cr | 33.401961 | +10.25% | -11.64% |
| LAURUSLABS | LAURUS LABS LIMITED | 105,487.98 cr | 96.587446 | +21.77% | +111.64% |
| MAXHEALTH | MAX HEALTHCARE INS LTD | 102,122.47 cr | 70.799892 | +14.33% | -10.58% |
Try these prompts
- Analyze BAL PHARMA. with valuation, momentum and industry peers
- Compare BALPHARMA with other Healthcare stocks
- Show small-cap stocks in Healthcare above 50DMA with positive 1M return
- Find Healthcare stocks with improving momentum and reasonable valuation
Related screen ideas
- View Healthcare stocks
- View small-cap stocks
- Find stocks above 50DMA
- Compare BALPHARMA with other Healthcare stocks
Data snapshot: 2026-09-18. Not investment advice.